<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00933998</url>
  </required_header>
  <id_info>
    <org_study_id>CMI-01</org_study_id>
    <nct_id>NCT00933998</nct_id>
  </id_info>
  <brief_title>Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®</brief_title>
  <official_title>Restoration of Cutaneous Sensorum in Patients With Diabetic Peripheral Neuropathy (DPN) Via Metanx®</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Carolina Musculoskeletal Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pamlab, L.L.C.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baylor University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Carolina Musculoskeletal Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to determine if Metanx improves sensory neuropathy in
      persons with Type 2 diabetes. Metanx is a medical food available with a prescription from a
      physician. It consists of L-methylfolate, Pyridoxal 5'-phosphate, and Methylcobalamin, which
      are the active forms of folate, vitamin B6, and vitamin B12, respectively. Subjects will be
      assigned to receive Metanx for 12 months. Baseline quantitative sensory testing will be done
      before the patient receives Metanx. Additional quantitative sensory testing will be done at 6
      and 12 months to evaluate.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2006</start_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Epidermal Nerve Density Count</measure>
    <time_frame>2 years</time_frame>
    <description>Measure increase or decrease in ENFD count after 12 months of Metanx therapy in patients with diabetic peripheral neuropathy</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Diabetic Peripheral Neuropathy</condition>
  <arm_group>
    <arm_group_label>Metanx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metanx bid for 2 weeks then daily. Compare to non treated patient population</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Metanx® (Oral L-methylfolate, Methylcobalamin and Pyridoxal 5'-phosphate)</intervention_name>
    <description>One pill twice a day for 2 weeks. Then one pill a day until 12 month study is up.</description>
    <arm_group_label>Metanx</arm_group_label>
    <other_name>Metanx</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Consecutive diabetic patients entering the office (private practice)

          -  Subjective symptoms of numbness, burning, paresthesia, etc.

          -  Failed Monofilament of at least two points on each foot

          -  Abnormal PSSD study

          -  Willing to participate in protocols or study

               -  Taking one Metanx tablet bid for 2 weeks then one Metanx tablet daily

               -  Keep scheduled appointments for follow up studies

               -  Report any other medical interventions, studies, or medication changes

               -  Report any problems of medical or psycho-social matters to investigators

               -  HgbA1c NOT monitored or specific value required for participation

        Exclusion Criteria:

          -  History of back problems (Surgery or ECSI) or other large fiber neuropathies

          -  History of chemotherapy

          -  History of chemical exposure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Carolina Musculoskeletal Institute</name>
      <address>
        <city>Aiken</city>
        <state>South Carolina</state>
        <zip>29841</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 7, 2009</study_first_submitted>
  <study_first_submitted_qc>July 7, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 8, 2009</study_first_posted>
  <last_update_submitted>January 28, 2014</last_update_submitted>
  <last_update_submitted_qc>January 28, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Carolina Musculoskeletal Institute</investigator_affiliation>
    <investigator_full_name>Mackie J. Walker, Jr., DPM</investigator_full_name>
    <investigator_title>Medical Director, Podiatry Division</investigator_title>
  </responsible_party>
  <keyword>DPN</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Peripheral Nervous System Diseases</mesh_term>
    <mesh_term>Diabetic Neuropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin B 12</mesh_term>
    <mesh_term>Pyridoxal</mesh_term>
    <mesh_term>Pyridoxal Phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

